Thus, in addition to the higher inhibitory effect exerted on insulin secretion compared with glucagon, SST5 agonists may indirectly regulate plasma glucose levels by affecting GLP-1 release, and SST5-targeting drugs may result in hyperglycaemia. This evidence concerns the gene SSTR5 and Hyperglycemia.